Symbol | Exchange | Currency |
|---|
Analysts at BofA and Goldman Sachs differed in their views following Zoetis' (NYSE:ZTS) analyst day, which was held on Thursday. Goldman Sachs, which maintained a Buy rating on the...
Zoetis Inc . (NYSE:ZTS) is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its...
Zoetis (NYSE: ZTS) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter...
Zoetis (NYSE:ZTS) declared a quarterly dividend of $0.375 per share, or $1.5 annualized. The dividend will be payable on September 1, 2023, to stockholders of record on July 21,...
Friday, the FDA approved Zoetis Inc's (NYSE: ZTS) Librela (bedinvetmab) for the control of pain associated with osteoarthritis (OA) in dogs. Librela is the first and only...
Investing.com - Zoetis Inc (NYSE: ZTS) reported first quarter EPS of $1.31, $0.06 better than the analyst estimate of $1.25. Revenue for the quarter came in at $2B versus the...
By Davit Kirakosyan Loop Capital upgraded Upstart Holdings Inc (NASDAQ:UPST) to Buy from Hold with a price target of $24.00 as the firm believes shares have reached a level...
Investing.com - Zoetis Inc (NYSE: ZTS) reported fourth quarter EPS of $1.15, in line with the analyst estimate of $1.15. Revenue for the quarter came in at $2B versus the consensus...